Postdoc in Human Pluripotent Stem Cell-based Cell Therapy for Type 1 Diabetes

Posted 1/9/2018

DanStem, University of Copenhagen

We are looking for a postdoctoral candidate with a strong cell biological and cell signaling background in directed differentiation of human pluripotent stem cells. Experience in differentiation towards pancreatic lineages is a merit. The candidate is expected to work on the engineering of human pluripotent stem cell-derived aggregates with functional properties close to human islets of Langerhans. The functionality and therapeutic potential of the aggregates will be tested in vitro and in vivo after transplantation into mice. The candidate is expected to use state-of-the-art genetic, molecular and cell biological, and tissue engineering experimental strategies. The candidate will work together with a dedicated team of scientists and technicians who together will tackle bottle-necks towards implementing the phase 1 clinical trials in T1D.

The position is for 2 years with a possible extension and planned to start as soon as possible or upon agreement.

DanStem addresses basic research questions in stem cell and developmental biology and has activities focused on the translation of promising basic research results into new strategies and targets for the development of new therapies for cancer and chronic diseases such as diabetes and liver failure (http://danstem.ku.dk).

Deadline for application is January 22, 2018.

Please find the full legal advertisement and link to on-line application on http://employment.ku.dk/faculty/?show=146407.

Last Updated 01/09/2018